ViroMissile, Inc.
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
ViroMissile is developing a new cornerstone of cancer treatments and turning immunologically cold tumors hot via our big breakthrough in effectively intravenously dosing an oncolytic virus (OV) as demonstrated by our emerging clinical data. We have demonstrated clear evidence of immune desert conversion, and we are able to do so by using a proprietary vaccinia-based OV platform that spreads quickly in tumors and survives in blood because it exists mostly as an enveloped form that is protected from immune system clearance. Our lead clinical program as part of a triplet combination therapy including PD-1 has demonstrated the industry’s highest response rates (ORR) and progression free survival (PFS) rates to date in MSS CRC, and our second clinical program as a monotherapy has helped our first two patients dosed achieve stable disease with solid tumors. ViroMissile has raised only $20M to date, and we are seeking a lead investor and/or pharma partner for a $40M series B.
Company HQ City:
La Jolla
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
IDOV-Safe has completed an IIT, and we are planning a registrational Phase 2 study.
CEO
Michael Wood, CBO
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
Our second program, IDOV-Immune, is reading out Phase 1 and IIT data later this year.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}